Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Phase I study of MST-16].

H Furue1, H Niitani, I Nakao

  • 1Teikyo University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 1, 1990
PubMed
Summary

Sobuzoxane (MST-16) demonstrated a favorable safety profile in Phase I trials. Recommended doses for Phase II studies were established based on administration schedules and observed toxicities, primarily leukopenia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationships between bone mass and dietary/lifestyle habits in Japanese women at 3-4 months postpartum.

Public health·2017
Same author

Specific HLA genotypes confer susceptibility to acute necrotizing encephalopathy.

Genes and immunity·2016
Same author

The impact of including corticosteroid in a periarticular injection for pain control after total knee arthroplasty: a double-blind randomised controlled trial.

The bone & joint journal·2016
Same author

Development of a high-volume air sampler for nanoparticles.

Environmental science. Processes & impacts·2014
Same author

X-linked CHARGE-like Abruzzo-Erickson syndrome and classic cleft palate with ankyloglossia result from TBX22 splicing mutations.

Clinical genetics·2012
Same author

Relationship between the number of outpatient visits for hypotension in the springtime in Japan, extracted from clinical electronic records, and global solar radiation levels.

The Journal of international medical research·2011

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Context:

  • MST-16 (Sobuzoxane) is a novel oral anticancer agent.
  • Understanding the safety and tolerability of new anticancer drugs is crucial for clinical development.

Purpose:

  • To evaluate the safety, tolerability, and preliminary efficacy of MST-16 in a Phase I clinical trial.
  • To determine the maximum tolerated dose (MTD) and recommended doses for Phase II studies across different administration schedules.

Summary:

  • The Phase I study investigated MST-16 using single, 5-day, and 10-15 day administration schedules.
  • Single administration showed no toxicity up to 1,500 mg/m2. Dose-dependent leukopenia and gastrointestinal disorders were observed with consecutive daily dosing.
  • One complete response was noted in a Hodgkin's disease patient. Recommended Phase II doses are 1,600 mg/body/day for 5 days and 1,200 mg/body/day for 10-14 days.

Impact:

  • Establishes safe dosing ranges for MST-16 in future clinical trials.
  • Provides essential data for the progression of Sobuzoxane into Phase II efficacy studies.
  • Contributes to the development of new oral anticancer therapies.

Related Experiment Videos